🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Inhaled treprostinil solution

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule terminated

    2 trials

  2. Inotersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule completed

    1 trial

  3. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

    Disc Medicine

    Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

    phase 3 small molecule active

    1 trial

  4. Intensive medical therapy

    Universal Integrated

    Myocardial Ischemia

    phase 3 other completed

    1 trial

  5. Intermediate-dose Cytarabine in Combination with Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  6. Intermittent hepatic inflow occlusion (IHIO)

    Samsung Bioepis NL B.V.

    End Stage Liver Disease

    phase 3 other active

    1 trial

  7. Intervention - a validated home BP monitor and support from the specialist nurse

    United Therapeutics Europe Ltd

    Stroke

    phase 3 other completed

    1 trial

  8. Intra-arterial thrombolysis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 other active

    1 trial

  9. Intranasal challenge drug

    Indivior Pty Ltd

    Heroin Dependence

    phase 3 small molecule completed

    1 trial

  10. Intrarosa 6.5 mg pessary

    Istituto Gentili S.r.l.

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  11. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 small molecule terminated

    1 trial

  12. Intravenous nicardipine hydrochloride

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule terminated

    1 trial

  13. Intravenous rhTNK-tPA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke, Acute Ischemic

    phase 3 small molecule active

    1 trial

  14. Intravenous thrombolysis plus tirofiban

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  15. Intravenous thrombolysis plus tirofiban

    Hospital Authority, Hong Kong

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  16. Investigator's choice of Chemotherapy

    Zentalis Pharmaceuticals

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  17. Iptacopan

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome

    phase 3 small molecule completed

    1 trial

  18. Irinotecan Accord, 20 mg/ml, koncentrat do sporządzania roztworu do infuzji, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cyramza 10 mg/ml concentrate for solution for

    AstraZeneca AB

    Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    phase 3 small molecule active

    1 trial

  19. Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Calciumfolinat Sandoz 10 mg/ml – Injektions-/Infusionslösung, SANIFOLIN polvere per soluzione iniettabile, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Paclitaxel Accord 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Cyramza 10 mg/ml c

    The George Institute

    advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

    phase 3 small molecule active

    1 trial

  20. Irinotecan liposome、5-Fluorouracil、Leucovorin

    Jian Li

    Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

    phase 3 small molecule completed

    1 trial

  21. Iron (27 mg) - folic acid (600 ug)

    United Therapeutics Europe Ltd

    Infant Mortality

    phase 3 other completed

    1 trial

  22. Isoniazid with Ethambutol

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  23. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, C1-esterase inhibitor

    Maze Therapeutics

    acute hereditary angioedema attacks

    phase 3 small molecule active

    1 trial

  24. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources